NOVAVAX INC — Form 10-Q
Filed August 6, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 5/100
What the filing says
John C. Jacobs (CEO) and James P. Kelly (CFO) issued routine Sarbanes-Oxley Section 302 and 906 certifications for Novavax's Q2 2026 10-Q (period ended June 30, 2026, filed August 6, 2026). Both certify financial statements fairly present material respects of financial condition, results of operations, and cash flows; both attest to disclosure controls and internal control over financial reporting design and effectiveness. No material changes, deficiencies, weaknesses, or fraud disclosures are stated.
Why this rating
Boilerplate executive certification exhibits; no business events, transactions, or operational changes disclosed. Standard periodic SEC compliance filing.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.